Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Sponsor: Canadian Cancer Trials Group
Study ID: NCT02879162
Phase: PHASE2
Status: Completed

Conditions

Advanced Rare Tumours

Eligibility Criteria

Sex: ALL
Age: 16 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Durvalumab — DRUG
Tremelimumab — DRUG

Study Details

The standard or usual treatment for this disease may be chemotherapy or other types of treatment to slow the spread of the disease and relieve some symptoms of this cancer.

Key Dates

Start date: Dec 14, 2016
Status verified: Jan 2025
Primary completion: Jun 20, 2021
Completion: Jan 29, 2025

Study Design

Enrollment: 140 participants (actual)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: Durvalumab + Tremelimumab
Durvalumab 1500 mg IV 60 min Day 1 every 4 weeks Tremelimumab 75 mg IV 60 min Day 1, cycles 1-4

Primary Outcome Measure

Objective Response Rate Measured by RECIST Version 1.1 [ Time Frame: 48 months ]